Adc Therapeutics Sa (ADCT) Stock Price & Analysis
Adc Therapeutics Sa (ADCT) rose 12.51% to USD 1.1 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
ADCT last closed at USD 0.98; the session ranged USD 0.97–1.16 on volume of 8,575,597 shares. Market capitalization is $139.91M, with a 52-week range of USD 0.78–4.98 (NYQ). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 1.1 |
|---|---|
| Change | ▲ 12.51% (up) |
| Previous Close | USD 0.98 |
| Open | USD 0.97 |
| Day Range | USD 0.97 – 1.16 |
| 52-Week Range | USD 0.78 – 4.98 |
| Volume | 8,575,597 shares |
| Market Cap | $139.91M |
| Exchange | NYQ |
Technical Analysis (ADCT)
Nexqual's technical model rates ADCT "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 13.63 (oversold) |
| vs SMA50 | Below (USD 3.47) |
| MACD | -0.6 (negative) |
Analyst Ratings (ADCT)
Wall Street analysts rate ADCT "Strong Buy" based on 5 analysts, with a mean price target of USD 5.6 (range USD 2–10), per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 5.6 |
| High Target | USD 10 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (ADCT)
| Next Earnings Date | 2026-08-05 |
|---|---|
| Revenue Estimate | $19.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.21 vs est -0.2 ▼ miss |
| 2025-12-31 | USD -0.04 vs est -0.27 ▲ beat |
| 2025-09-30 | USD -0.3 vs est -0.36 ▲ beat |
| 2025-06-30 | USD -0.5 vs est -0.48 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (ADCT)
| Total Revenue | $79.17M |
|---|---|
| Revenue Growth (YoY) | -9.50% |
| Gross Margin | -26.33% |
| Operating Margin | -121.07% |
| Profit Margin | -173.02% |
| Current Ratio | 4.09 |
| Total Cash | $231.01M |
| Total Debt | $436.26M |
| Free Cash Flow | $-74.85M |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (ADCT)
Nexqual rates Adc Therapeutics Sa's overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Solid — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $231M cash vs $436M debt |
| Cash Flow | Weak — FCF negative: -$75M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ADCT)
| Insider Ownership | +13.44% |
|---|---|
| Institutional Ownership | +67.58% |
| Shares Outstanding | 127.19M |
| Float | 100.41M |
| Short % of Float | +5.33% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Leadership (ADCT)
Adc Therapeutics Sa is led by Ameet Mallik M.B.A., M.S. (age 52), CEO & Director, per Nexqual as of June 9, 2026 at 23:51 UTC.
| CEO & Director | Ameet Mallik M.B.A., M.S. (age 52) |
|---|---|
| Chief Financial Officer | Jose I. Carmona (age 53) |
Major Backers & Investors (ADCT)
Notable institutional backers of Adc Therapeutics Sa include Redmile Group, LLC, TCG Crossover Management, LLC, Prosight Management, Lp, according to Nexqual as of June 9, 2026 at 23:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Redmile Group, LLC | 12.16% |
| TCG Crossover Management, LLC | 8.96% |
| Prosight Management, Lp | 6.53% |
| Eventide Asset Management LLC | 4.48% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 4.48% |
| Nantahala Capital Management, LLC | 4.4% |
| Morgan Stanley | 3% |
| Point72 Asset Management, L.P. | 2.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.14% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
From Adc Therapeutics Sa's Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States.
- Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
- Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
- The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CIEN | Ciena Corporation | USD 439.34 | ▼ 10.01% |
| COMS | COMSovereign Holding Corp. | USD 0 | ▲ 0% |
| ADTN | ADTRAN Holdings, Inc. | USD 14.26 | ▼ 7.1% |
| CPWR | Ocean Thermal Energy Corp. | USD 0.01 | ▼ 22.22% |
| ADPT | Adaptive Biotechnologies Corpor | USD 17.36 | ▲ 2.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.